Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Immunotherapy. M. D. Anderson Cancer Center, Houston, TX, United States

Survival: 30.0 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Houston, TX
Hospital: M. D. Anderson Cancer Center
Journal: Link
Date: 11/2007

Patients: This phase II study involved 150 patients with androgen-independent prostate cancer. The majority (100) of the men were between the ages of 50 and 70 years old. These patients had not received a previous treatment with chemotherapy.

Treatment: Patients were treated with one of four drug combinations. These were: Cyclophosphamide, vincristine, and dexamethasone; ketoconazole and doxorubicin with alternating treatments with vinblastine and estramustine; paclitaxel, estramustine, and carboplatin; or paclitaxel, estramustine, and etoposide. If patients did not respond, they were put on one of the other treatment regimens. Symptoms, regression of the tumor, and prostate-specific antigen in patients were used to determine a response to treatment.

Toxicity: Two treatment-related deaths were reported. Thirteen grade 4 toxicites were reported. They were thrombosis/embolism, dyspnea, ureteral obstruction, febrile neutropenia, vomiting, confusion, hypoglycemia, delusions, and musculoskeletal/fracture.

Result: The median overall survival was 22 months. The median survival of patients who had ‘overall success’ as determined by the researchers was 30 months. This group consisted of 44 patients, and 35 of them responded to the first treatment they were given. For the other 106 patients in the study, the median survival time was 19 months.

Correspondence: Dr. Herman P. Pressler

E-mail to a Friend Email Physician More Information